All In Biotech

Drug Trial Radar · NCT02004522

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO)

Last checked: Nov 19, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 319 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

319

Actual

Start

Nov 2013

Primary completion

May 19, 2017

Study completion Jun 2021

Sponsor

Lead sponsor
SecuraBioIndustry
Sponsor type
Industry
First posted
Dec 9, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 3 clinical trial to examine the efficacy of duvelisib monotherapy versus ofatumumab monotherapy in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).

Conditions

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Interventions

  • DuvelisibDrug

    PI3K Inhibitor

  • OfatumumabDrug

    monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years

Locations

92 sites in 11 countries. Site status is shown where the registry gives one.

  • Site not named

    La Jolla, California

  • Site not named

    Denver, Colorado

  • Site not named

    Altamonte Springs, Florida

  • Site not named

    Bonita Springs, Florida

  • Site not named

    Bradenton, Florida

  • Site not named

    Brandon, Florida

  • Site not named

    Cape Coral, Florida

  • Site not named

    Clearwater, Florida

  • Site not named

    Englewood, Florida

  • Site not named

    Fort Myers, Florida

  • Site not named

    Gainesville, Florida

  • Site not named

    Hudson, Florida

  • Site not named

    Inverness, Florida

  • Site not named

    Largo, Florida

  • Site not named

    Naples, Florida

  • Site not named

    New Port Richey, Florida

  • Site not named

    Orange City, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Port Charlotte, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    Spring Hill, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Tavares, Florida

  • Site not named

    Venice, Florida

  • Site not named

    Crestview Hills, Kentucky

  • Site not named

    Boston, Massachusetts

  • Site not named

    Boston, Massachusetts

  • Site not named

    St Louis, Missouri

  • Site not named

    Hackensack, New Jersey

  • Site not named

    New Brunswick, New Jersey

  • Site not named

    New York, New York

  • Site not named

    New York, New York

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Fairfield, Ohio

  • Site not named

    Nashville, Tennessee

  • Site not named

    Charlottesville, Virginia

  • Site not named

    Bedford Park, Australia

  • Site not named

    East Melbourne, Australia

  • Site not named

    Melbourne, Australia

Showing 40 of 92 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.